Remarks/Arguments

Applicants have amended the specification to provide the priority claim. Claims 7-10 have been amended. Claim 6 has been cancelled without prejudice for resubmission. New claims 12-19 have been added. Claims 1-5 and 7-19 are pending after entry of this amendment. The claims have been amended to remove multiple dependencies and to otherwise place the claims in an appropriate U.S. format. The support for the newly added claims can be found in the originally filed claims. No new matter has been added by these amendments.

Applicants believe the application is in condition for allowance, which action is respectfully requested.

The Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 26-0166, referencing Attorney Docket No. 100953-1P US.

Respectfully submitted,

July 7, 2005

Kenneth F. Mitchell for Jianzhong Shen

Name: Kenneth F. Mitchell

Dated: July 7, 2005 Reg. No. 42,007

Phone No. 302-886-7466 Name: Jianzhong Shen

Reg. No. 48,076

Phone No. 302-886-8854

Global Intellectual Property, Patents,

AstraZeneca,

1800 Concord Pike,

Wilmington,

DE-19850-5437